VR Logo

Marinus Pharmaceuticals Inc. (MRNS) download report


Healthcare | Biotechnology & Pharma Research

Marinus Pharmaceuticals Inc. (MRNS) Premium Coverage

52 Stocks to buy right now

Join Value Research Stock Advisor now and be among the first to discover Stock Ideas

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

About The Company

Business: Marinus Pharmaceuticals, Inc., a pharmaceutical company, focuses on development and commercialization of products for patients suffering from rare genetic epilepsies and other seizure disorders.

IPO Date: 31-Jul-2014

CEO, Pres & Director: Dr. Scott N. Braunstein M.D.

CFO & Treasurer: Mr. Steven E. Pfanstiel C.M.A., M.B.A.

Listing: NASDAQ: MRNS

Country: United States

Headquarters: Radnor, PA

Website: https://marinuspharma.com

Key Facts

Market cap: $182.38 Mln

Revenue (TTM): $17.61 Mln

Earnings (TTM): $-91.00 Mln

Cash: $126.32 Mln

Total Debt: $72.33 Mln

Insider's Holding: 0.52%

Liquidity: Low

52 Week range: $3.97 - 19.38

Shares outstanding: 37,140,400

10 Years Aggregate:

  • CFO: $-273.02 Mln
  • EBITDA: $-344.96 Mln
  • Net Profit: $-347.00 Mln

Stock Performance

Time Period Marinus Pharmaceuticals (MRNS) S&P BSE Sensex* S&P Small-Cap 600*
YTD-59.60-8.99-19.22
1 month-5.88-3.40-9.34
3 months-51.27-8.50-14.58
1 Year-74.070.89-17.64
3 Years-33.8710.415.91
5 Years-3.0411.435.64
10 Years--11.7710.10
As on 29-Jun-2022 *As on 30-Jun-2022
Year Marinus Pharmaceuticals (MRNS) S&P Small-Cap 600 S&P BSE Sensex
2021-2.6225.2721.99
202041.209.5715.75
2019-24.7420.8614.38
2018-64.63-9.705.87
2017707.9211.7327.91
2016-86.7824.741.95
2015-27.72-3.36-5.03